Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date ...

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a ...

GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

I was prescribed the drugs tambulosin and finasteride for an enlarged prostate. But I was never warned that they might make ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response.

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, suggest adding an inhaled corticosteroid to rescue therapy could sharply ...

Regulatory decisions on the remaining three — Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps) and Nucala (for COPD ...